In conclusion, using this model, the efficacy and safety of MOv18 IgE were demonstrated simultaneously: IgE-treated animals did not suffer from toxicities, cytokine storm or allergic reactions, suggesting that administration of MOv18 IgE can be safe and supporting translation of the therapeutic candidate to clinical testing in man. Here, IGHE is linked to allergic disease.